Sign in
Create a Profile
Previous
A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD.
Diseases and Conditions Researched
Coronary Artery Disease
What is the purpose of this trial?
The primary objective of the study is to assess the diagnostic efficacy (specificity and sensitivity) of flurpiridaz F18 injection PET myocardial perfusion imaging (MPI) compared to single photon emission computed tomography (SPECT) MPI in the detection of significant coronary artery disease (CAD) as defined by invasive coronary angiography (ICA) or a documented history of Myocardial Infarction (MI).
Participation Guidelines
Gender: Both
Click here for detailed participation information for this trial.
| Sponsor: | Lantheus Medical Imaging |
|---|---|
| Dates: | April 11, 2011 |
| Last Updated: | November 9, 2012 |
| Study HIC#: | 1102008091 |
| Clinicaltrials.gov ID: | NCT01347710 |
How will my information be used?
For more information about this trial, contact:
Albert Sinusas, M.D.
203-785-5005
albert.sinusas@yale.edu
Donna McMahon
203-785-5005
donna.mcmahon@yale.edu
Principal Investigator
Albert Sinusas, M.D.
How will my information be used?
When you express interest in a specific study, the information from your profile will be sent to the doctor conducting that study. If you're eligible to participate, you may be contacted by a nurse or study coordinator.
If you select a health category rather than a specific study, doctors who have active studies in that area may contact you to ask if you would like to participate.
In both cases, you will be contacted by the preferred method (email or phone) that you specified in your profile.
